RÉSUMÉ
Intravenous thrombolysis is the standard treatment for acute ischemic stroke. We here report the cases of thrombolysis alert in the private sector in Morocco We conducted a prospective study of all patients with neurological deficit of sudden onset occurred within the first 12 hours admitted to the Emergency Department of the Al Badie international private clinic from January 2022 to September 2023. Epidemiological, clinical and etiological characteristics as well as data on outpatient and inpatient delays were collected. Sixty patients were included in the study. The average admission delay was 198.36 ± 79.23 minutes. The mean NIHSS (National Institutes of Health Stroke Scale) score was 10.41 ± 4.97. The average time for imaging was 26.68 ± 9.63 minutes. Ischaemic stroke was the most common diagnosis (85%), followed by "stroke mimics" (11.6%). Thirteen patients underwent thrombolysis with tenecteplase. The mean time from admission to the initiation of thrombolysis was 107.15 ± 24.48 minutes. Follow-up imaging at 24 hours post thrombolysis revealed symptomatic haemorrhagic transformation in 3 patients. Six patients were transferred to the Hassan II University Hospital for thrombolysis and/or mechanical thrombectomy. After 3 months, 4 patients were autonomous (Rankin score changed between 0 and 2). Our experience shows that it is imperative to reduce outpatient and inpatient delays in treatment in order to increase the proportion of patients treated with thrombolysis.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Traitement thrombolytique , Délai jusqu'au traitement , Humains , Maroc , Femelle , Adulte d'âge moyen , Accident vasculaire cérébral ischémique/traitement médicamenteux , Mâle , Traitement thrombolytique/méthodes , Traitement thrombolytique/effets indésirables , Études prospectives , Sujet âgé , Fibrinolytiques/administration et posologie , Fibrinolytiques/effets indésirables , Études transversales , Adulte , Ténectéplase/administration et posologie , Ténectéplase/effets indésirables , Service hospitalier d'urgences/statistiques et données numériques , Facteurs temps , Thrombectomie/méthodes , Études de suivi , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/effets indésirables , Sujet âgé de 80 ans ou plusRÉSUMÉ
INTRO: Current guidelines for acute ischemic stroke recommend timely administration of intravascular thrombolytic therapy to promote functional and neurologic outcomes. Tenecteplase is an emerging off-label therapy for this indication and being utilized by various institutions due to its simpler administration strategy. In emergent situations in which intravenous access cannot be obtained, intraosseous access is a viable option for medication administration. However, there has been minimal published cases to support the efficacy and safety of intraosseous administration of tenecteplase for acute ischemic stroke. CASE: We describe the case of a 51-year-old woman who developed acute ischemic stroke within our institution. Due to difficulty achieving intravenous access and time-dependent efficacy of thrombolytic therapy, the decision was made to administer tenecteplase by the intraosseous route. Stroke symptoms improved within 48 hours following administration without complication. CONCLUSION: Intraosseous administration of tenecteplase may be considered for treatment of acute ischemic stroke if intravenous access is unattainable.
Sujet(s)
Fibrinolytiques , Perfusions intraosseuses , Accident vasculaire cérébral ischémique , Ténectéplase , Traitement thrombolytique , Humains , Ténectéplase/administration et posologie , Adulte d'âge moyen , Femelle , Fibrinolytiques/administration et posologie , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/diagnostic , Accident vasculaire cérébral ischémique/imagerie diagnostique , Résultat thérapeutique , Activateur tissulaire du plasminogène/administration et posologie , Facteurs tempsRÉSUMÉ
INTRODUCTION: United States stroke systems are increasingly transitioning from alteplase (TPA) to tenecteplase (TNK). Real-world data on the safety and effectiveness of replacing TPA with TNK before large vessel occlusion (LVO) stroke endovascular treatment (EVT) are lacking. METHODS: Four Pennsylvania stroke systems transitioned from TPA to TNK during the study period 01/2020-06/2023. LVO stroke patients who received intravenous thrombolysis with TPA or TNK before EVT were reviewed. Multivariate logistic analysis was conducted adjusting for age, sex, National Institute of Health Stroke Scale (NIHSS), occlusion site, last-known-well-to-intravenous thrombolysis time, interhospital-transfer and stroke system. RESULTS: Of 635 patients, 309 (48.7%) received TNK and 326 (51.3%) TPA prior to EVT. The site of occlusion was the M1 middle cerebral artery (MCA) (47.7%), M2 MCA (25.4%), internal carotid artery (14.0%), tandem carotid with M1 or M2 MCA (9.8%) and basilar artery (3.1%). A favorable functional outcome (90-day mRS ≤ 2) was observed in 47.6% of TNK and 49.7% of TPA patients (p = 0.132). TNK versus TPA groups had similar rates of early recanalization (11.9% vs. 8.4%, p = 0.259), successful endovascular reperfusion (93.5% vs. 89.3%, p = 0.627), symptomatic intracranial hemorrhage (3.2% vs. 3.4%, p = 0.218) and 90-day all-cause mortality (23.1% vs. 21.5%, p = 0.491). CONCLUSIONS: This U.S. multicenter real-world clinical experience demonstrated that switching from TPA to TNK before EVT for LVO stroke resulted in similar endovascular reperfusion, safety, and functional outcomes.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Ténectéplase , Thrombectomie , Activateur tissulaire du plasminogène , Humains , Mâle , Femelle , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/pharmacologie , Sujet âgé , Ténectéplase/administration et posologie , Fibrinolytiques/administration et posologie , Adulte d'âge moyen , Thrombectomie/méthodes , Pennsylvanie , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/thérapie , Accident vasculaire cérébral ischémique/chirurgie , Sujet âgé de 80 ans ou plus , Procédures endovasculaires , Traitement thrombolytique/méthodes , Résultat thérapeutique , Accident vasculaire cérébral/traitement médicamenteux , Accident vasculaire cérébral/thérapieRÉSUMÉ
Central retinal artery occlusion (CRAO), a type of acute retinal arterial ischemia, analogous to an ocular stroke, is a medical emergency that warrants immediate diagnosis and treatment. CRAO usually presents with sudden, painless, monocular vision loss. Ipsilateral carotid artery disease is an important associated finding in these patients. The primary limitation to effective treatment of CRAO is that patients are rarely seen in the acute stage. Moreover, there are no guidelines for effective treatment. We report a patient with right CRAO whose treatment with intravenous thrombolysis with tenecteplase and anterior chamber paracentesis with ocular massage resulted in a good clinical outcome.
Sujet(s)
Fibrinolytiques , Occlusion artérielle rétinienne , Ténectéplase , Traitement thrombolytique , Humains , Ténectéplase/usage thérapeutique , Ténectéplase/administration et posologie , Fibrinolytiques/usage thérapeutique , Occlusion artérielle rétinienne/diagnostic , Occlusion artérielle rétinienne/traitement médicamenteux , Traitement thrombolytique/méthodes , Maladie aigüe , Mâle , Activateur tissulaire du plasminogène/usage thérapeutique , Activateur tissulaire du plasminogène/administration et posologie , Ischémie/diagnostic , Ischémie/traitement médicamenteux , Adulte d'âge moyen , Angiographie fluorescéinique/méthodes , Femelle , Sujet âgéRÉSUMÉ
BACKGROUND: Intravenous tenecteplase increases reperfusion in patients with salvageable brain tissue on perfusion imaging and might have advantages over alteplase as a thrombolytic for ischaemic stroke. We aimed to assess the non-inferiority of tenecteplase versus alteplase on clinical outcomes in patients selected by use of perfusion imaging. METHODS: This international, multicentre, open-label, parallel-group, randomised, clinical non-inferiority trial enrolled patients from 35 hospitals in eight countries. Participants were aged 18 years or older, within 4·5 h of ischaemic stroke onset or last known well, were not being considered for endovascular thrombectomy, and met target mismatch criteria on brain perfusion imaging. Patients were randomly assigned (1:1) by use of a centralised web server with randomly permuted blocks to intravenous tenecteplase (0·25 mg/kg) or alteplase (0·90 mg/kg). The primary outcome was the proportion of patients without disability (modified Rankin Scale 0-1) at 3 months, assessed via masked review in both the intention-to-treat and per-protocol populations. We aimed to recruit 832 participants to yield 90% power (one-sided alpha=0·025) to detect a risk difference of 0·08, with an absolute non-inferiority margin of -0·03. The trial was registered with the Australian New Zealand Clinical Trials Registry, ACTRN12613000243718, and the European Union Clinical Trials Register, EudraCT Number 2015-002657-36, and it is completed. FINDINGS: Recruitment ceased early following the announcement of other trial results showing non-inferiority of tenecteplase versus alteplase. Between March 21, 2014, and Oct 20, 2023, 680 patients were enrolled and randomly assigned to tenecteplase (n=339) and alteplase (n=341), all of whom were included in the intention-to-treat analysis (multiple imputation was used to account for missing primary outcome data for five patients). Protocol violations occurred in 74 participants, thus the per-protocol population comprised 601 people (295 in the tenecteplase group and 306 in the alteplase group). Participants had a median age of 74 years (IQR 63-82), baseline National Institutes of Health Stroke Scale score of 7 (4-11), and 260 (38%) were female. In the intention-to-treat analysis, the primary outcome occurred in 191 (57%) of 335 participants allocated to tenecteplase and 188 (55%) of 340 participants allocated to alteplase (standardised risk difference [SRD]=0·03 [95% CI -0·033 to 0·10], one-tailed pnon-inferiority=0·031). In the per-protocol analysis, the primary outcome occurred in 173 (59%) of 295 participants allocated to tenecteplase and 171 (56%) of 306 participants allocated to alteplase (SRD 0·05 [-0·02 to 0·12], one-tailed pnon-inferiority=0·01). Nine (3%) of 337 patients in the tenecteplase group and six (2%) of 340 in the alteplase group had symptomatic intracranial haemorrhage (unadjusted risk difference=0·01 [95% CI -0·01 to 0·03]) and 23 (7%) of 335 and 15 (4%) of 340 died within 90 days of starting treatment (SRD 0·02 [95% CI -0·02 to 0·05]). INTERPRETATION: The findings in our study provide further evidence to strengthen the assertion of the non-inferiority of tenecteplase to alteplase, specifically when perfusion imaging has been used to identify reperfusion-eligible stroke patients. Although non-inferiority was achieved in the per-protocol population, it was not reached in the intention-to-treat analysis, possibly due to sample size limtations. Nonetheless, large-scale implementation of perfusion CT to assist in patient selection for intravenous thrombolysis in the early time window was shown to be feasible. FUNDING: Australian National Health Medical Research Council; Boehringer Ingelheim.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Imagerie de perfusion , Ténectéplase , Activateur tissulaire du plasminogène , Humains , Ténectéplase/usage thérapeutique , Ténectéplase/administration et posologie , Mâle , Femelle , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/imagerie diagnostique , Activateur tissulaire du plasminogène/usage thérapeutique , Activateur tissulaire du plasminogène/administration et posologie , Sujet âgé , Fibrinolytiques/usage thérapeutique , Fibrinolytiques/administration et posologie , Adulte d'âge moyen , Imagerie de perfusion/méthodes , Traitement thrombolytique/méthodes , Résultat thérapeutique , Sujet âgé de 80 ans ou plusRÉSUMÉ
OBJECTIVE: We sought to describe short term outcomes in patients with large vessel occlusion acute ischemic stroke (LVOAIS) who were treated with intravenous tenecteplase (TNK) as compared to alteplase (tPA), focusing on reduction in the need for mechanical thrombectomy (MT). BACKGROUND: In LVOAIS, TNK has shown improved reperfusion and outcomes with a similar safety profile to tPA. Ultra-early reperfusion has been described with TNK which would prevent the need for MT. We analyze the magnitude of this effect in a "real-world" setting. DESIGN/METHODS: In this retrospective study, demographic, clinical, and imaging information from patients with LVOAIS treated with intravenous thrombolysis was collected. Data was compared between the group treated with TNK and tPA. RESULTS: One hundred eighty-six patients met the criteria for the study. Of these,144patients received tPA and 42 received TNK. Nine had clinical improvement prior to groin puncture and did not require angiography. When combining the number of patients who had recanalization on angiography before MT and those who had clinical improvement prior to angiography, there were a total of 23 patients. This was noted in 9.7 % of patients who received tPA and 21.4 % of those who received TNK (p = 0.043). For patients treated with TNK we observed a rapid clinical improvement, improved NIHSS, improved functional outcomes and decreased length of stay compared to patients treated with tPA. For patients with spontaneous recanalization either angiographically or with clinical improvement from intravenous thrombolysis, MT may not be required. CONCLUSIONS: Intravenous TNK in patients with LVOAIS decreases the need for MT, and is associated with improved outcomes and reduced length of stay.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Ténectéplase , Thrombectomie , Activateur tissulaire du plasminogène , Humains , Études rétrospectives , Mâle , Ténectéplase/administration et posologie , Ténectéplase/usage thérapeutique , Femelle , Fibrinolytiques/administration et posologie , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/thérapie , Sujet âgé , Adulte d'âge moyen , Thrombectomie/méthodes , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/usage thérapeutique , Résultat thérapeutique , Administration par voie intraveineuse , Sujet âgé de 80 ans ou plus , Traitement thrombolytique/méthodesSujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Ténectéplase , Thrombectomie , Délai jusqu'au traitement , Humains , Fibrinolytiques/administration et posologie , Fibrinolytiques/usage thérapeutique , Accident vasculaire cérébral ischémique/imagerie diagnostique , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/étiologie , Accident vasculaire cérébral/imagerie diagnostique , Accident vasculaire cérébral/traitement médicamenteux , Traitement thrombolytique , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/usage thérapeutique , Thrombectomie/méthodes , Procédures endovasculaires , État fonctionnel , Récupération fonctionnelle , Ténectéplase/administration et posologie , Ténectéplase/usage thérapeutique , Essais contrôlés randomisés comme sujet , InternationalitéRÉSUMÉ
OBJECTIVES: To investigate the safety of administering low-dose aspirin (81 mg) 18 hours after intravenous thrombolytic therapy. METHODS: This is a retrospective cohort investigation. Individuals received either alteplase or tenecteplase for acute ischemic stroke followed by aspirin 81 mg (after follow-up imaging). An institutional change moved follow-up post-thrombolytic CT scans to 18 hours, and qualifying patients were grouped based on whether they received aspirin ≤24 hours or >24 hours. Chart reviews were conducted to assess the primary outcome of new or worsening intracranial hemorrhage, as well as secondary outcomes of change in stroke scale scores at discharge and 3 months, lengths of stay, favorable outcomes at 3 months, hospital readmission, and mortality. RESULTS: Out of 350 patients screened, 130 qualified for inclusion-50 of whom received aspirin ≤24 hours (mean 21.1 hours, SD±6.2), and 80 who received aspirin >24 hours (mean 34 hours, SD±8.2). Only 1 new intracranial bleed occurred following aspirin administration in the >24-hour group. No statistically significant differences were observed in any of the secondary outcomes, although there was higher mortality (3/50 vs. 2/80, P =0.372) and shorter hospital length of stay (median difference -1.0 day, P =0.0336) in the <24 hours group. CONCLUSIONS: Low-dose aspirin administration sooner than 24 hours following thrombolytic therapy did not increase bleeding events. Sooner aspirin administration after ischemic stroke can potentially enhance the prevention of secondary embolization and did not demonstrate worse clinical outcomes; however, further randomized controlled trials are needed.
Sujet(s)
Acide acétylsalicylique , Fibrinolytiques , Accident vasculaire cérébral ischémique , Traitement thrombolytique , Humains , Acide acétylsalicylique/administration et posologie , Mâle , Femelle , Accident vasculaire cérébral ischémique/traitement médicamenteux , Sujet âgé , Études rétrospectives , Adulte d'âge moyen , Fibrinolytiques/administration et posologie , Fibrinolytiques/effets indésirables , Traitement thrombolytique/méthodes , Traitement thrombolytique/effets indésirables , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/effets indésirables , Activateur tissulaire du plasminogène/usage thérapeutique , Sujet âgé de 80 ans ou plus , Facteurs temps , Antiagrégants plaquettaires/administration et posologie , Résultat thérapeutique , Ténectéplase/administration et posologie , Hémorragies intracrâniennes/induit chimiquementRÉSUMÉ
OBJECTIVES: Tenecteplase (TNK) is a promising alternative to alteplase (ALT) as the thrombolytic agent for acute ischemic stroke (AIS). However, its clinical outcomes in certain populations remain unclear. This study aimed to compare the efficacy and safety among different doses of TNK in AIS patients. METHODS: We searched PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Embase for studies comparing at least one dose of TNK to another dose of TNK or ALT 0.90 mg/kg. We conducted Bayesian network meta-analyses to estimate the relative risks (RRs) and 95% credible intervals (CrIs) for all outcomes using ALT 0.90 mg/kg as the reference. The treatments were ranked according to their surface under the cumulative ranking (SUCRA) values. RESULTS: We included 11 trials from 16 publications comprising 5423 participants. There were no significant differences between any doses of TNK and ALT for reperfusion, 3-month modified Rankin Score (mRS) 0-1 (rank 1st: TNK 0.25 mg/kg; SUCRA = 0.68), mRS 0-2 (rank 1st: TNK 0.25 mg/kg; SUCRA = 0.86), mortality (rank 1st: TNK 0.25 mg/kg; SUCRA = 0.82), intracranial hemorrhage (ICH) (rank 1st: TNK 0.25 mg/kg; SUCRA = 0.88), symptomatic ICH (sICH) (rank 1st: TNK 0.10 mg/kg; SUCRA = 0.70), and parenchymal hematoma (rank 1st: TNK 0.10 mg/kg; SUCRA = 0.68). TNK 0.40 mg/kg had a significantly higher sICH rate compared to TNK 0.25 mg/kg (RR = 2.39, 95% CrI = 1.00-7.92). Among elderly patients, TNK 0.25 mg/kg had a significantly lower rate of sICH than ALT 0.9 mg/kg (RR = 3.0 × 10-13, 95% CrI = 3.4 × 10-40-0.07). CONCLUSIONS: TNK has efficacy and safety outcomes comparable to those of ALT. TNK 0.25 mg/kg may be the optimal dose of TNK for patients with AIS.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Méta-analyse en réseau , Ténectéplase , Humains , Fibrinolytiques/administration et posologie , Fibrinolytiques/effets indésirables , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/diagnostic , Ténectéplase/administration et posologie , Ténectéplase/effets indésirables , Résultat thérapeutique , Sujet âgé , Mâle , Femelle , Adulte d'âge moyen , Traitement thrombolytique/effets indésirables , Facteurs de risque , Sujet âgé de 80 ans ou plus , Facteurs temps , Récupération fonctionnelle , Évaluation de l'invalidité , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/effets indésirablesRÉSUMÉ
Objective: To investigate the efficacy and safety of intravenous thrombolysis with Tenecteplase (TNK) in patients with post-awakening branch atheromatous disease (BAD). Methods: A retrospective collection was conducted on 178 patients with post-awakening BAD admitted to the Stroke Centre of Zhengzhou People's Hospital from January 2017 to June 2023, who had a mismatch in DWI/FLAIR on magnetic resonance imaging. The patients were divided into thrombolysis group (60 patients) and control group (118 patients) according to whether or not they were applied to intravenous thrombolysis by TNK. Propensity score matching (PSM) was used to pair and balance the confounding factors at 1â¶1 between the two groups, and the 90-d long-term prognosis of the patients was assessed using the modified Rankin Scale (mRS) and the Barthel Index (BI). The National Institutes of Health Stroke Scale (NIHSS) score was used to compare the early neurological changes between the two groups.The differences in clinical outcomes were compared between the two groups. Results: Fifty-two pairs of patients, 65 males and 39 females, aged (60±9) years, were successfully matched by PSM. The thrombolysis group had lower NIHSS score than that of the control group at 24 h, 7 d, 14 d after treatment or at discharge [3(2, 5) vs 4(3, 7), 3(2, 5) vs 4(3, 5), and 2(1, 4) vs 3(2, 4)], and shorter hospital stay than that of the control group [9(7, 12) d vs 11(9, 13) d], and at the same time, the thrombolysis group was less likely to experience early neurological deterioration (END) [9.6% (5/52) vs 28.9% (15/52)], and the proportion of 90 d mRS≤1, mRS≤2, and BI scores were higher than those in the control group [63.5% (33/52) vs 30.8% (16/52), 82.7% (43/52) vs 59.6% (31/52), and (91±8) points vs (82±8) points ], all differences were statistically significant (P<0.05). The percentage of mRS≥4 points was higher in the control group than that in the thrombolysis group [23.1% (12/52) vs 7.7% (4/52)]. One case of intracranial haemorrhage occurred in the thrombolysis group, and 1 case in the control group died of pulmonary infection within 90 d of follow-up, with a case-fatality rate of 1.9% (1/52). Conclusion: In the patients with post-awakening BAD screened by MRI, TNK intravenous thrombolysis can significantly reduce the risk of END, improving long-term prognosis and has a high safety.
Sujet(s)
Fibrinolytiques , Ténectéplase , Traitement thrombolytique , Humains , Femelle , Mâle , Adulte d'âge moyen , Études rétrospectives , Ténectéplase/administration et posologie , Ténectéplase/usage thérapeutique , Fibrinolytiques/usage thérapeutique , Fibrinolytiques/administration et posologie , Administration par voie intraveineuse , Résultat thérapeutique , Accident vasculaire cérébral/traitement médicamenteux , Sujet âgé , Activateur tissulaire du plasminogène/usage thérapeutique , Activateur tissulaire du plasminogène/administration et posologie , Pronostic , Score de propensionRÉSUMÉ
BACKGROUND: The benefits and risks of tenecteplase (TNK) versus alteplase (ALT) have recently been assessed in acute ischemic stroke (AIS) patients undergoing mechanical thrombectomy (MT) with diverse results. Due to its high fibrin specificity and lack of excitotoxicity, TNK may have a higher efficacy and safety profile. This study aimed to evaluate the benefits and risks of TNK compared to ALT in AIS patients prior to thrombectomy. METHODS: We systematically searched four key databases, PubMed, Embase, Web of Science and Cochrane Library until January 27, 2024 for clinical studies evaluating the effects of TNK versus ALT in patients with large vessel occlusion undergoing MT. A random-effect meta-analysis was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: Ten studies involving 3722 patients receiving TNK (1266 patients) or ALT (2456 patients) were included (age: 69.05 ± 14.95 years; 55.64% male). Compared to ALT-treated patients, TNK-treated patients demonstrated significantly higher rates of early recanalization (odds ratio 2.02, 95%-confidence interval 1.20-3.38, p = 0.008) without increased risk of symptomatic intracerebral hemorrhage (1.06, 0.64-1.76, p = 0.82) or intracerebral hemorrhage (1.21, 0.66-2.25, p = 0.54). TNK-treated patients showed similar rates of functional independence at 90 days (1.13, 0.87-1.46, p = 0.37) as ALT-treated patients, but lower rates of mortality within 90 days (0.65, 0.44-0.96, p = 0.03). CONCLUSION: TNK is superior to ALT in achieving early recanalization and is associated with lower mortality within 90 days in AIS patients undergoing MT. Compared with ALT, TNK does not significantly alter functional independence at 90 days, symptomatic intracerebral hemorrhage or intracerebral hemorrhage.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Ténectéplase , Thrombectomie , Activateur tissulaire du plasminogène , Sujet âgé , Humains , Fibrinolytiques/administration et posologie , Fibrinolytiques/effets indésirables , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/chirurgie , Ténectéplase/administration et posologie , Thrombectomie/méthodes , Thrombectomie/effets indésirables , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/pharmacologie , Activateur tissulaire du plasminogène/effets indésirables , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé de 80 ans ou plusRÉSUMÉ
BACKGROUND: Tenecteplase (TNK) is considered a promising option for the treatment of acute ischemic stroke (AIS) with the potential to decrease door-to-needle times (DTN). This study investigates DTN metrics and trends after transition to tenecteplase. METHODS: The Lone Star Stroke (LSS) Research Consortium TNK registry incorporated data from three Texas hospitals that transitioned to TNK. Subject data mapped to Get-With-the-Guidelines stroke variables from October 1, 2019 to March 31, 2023 were limited to patients who received either alteplase (ALT) or TNK within the 90 min DTN times. The dataset was stratified into ALT and TNK cohorts with univariate tables for each measured variable and further analyzed using descriptive statistics. Logistic regression models were constructed for both ALT and TNK to investigate trends in DTN times. RESULTS: In the overall cohort, the TNK cohort (n = 151) and ALT cohort (n = 161) exhibited comparable population demographics, differing only in a higher prevalence of White individuals in the TNK cohort. Both cohorts demonstrated similar clinical parameters, including mean NIHSS, blood glucose levels, and systolic blood pressure at admission. In the univariate analysis, no difference was observed in median DTN time within the 90 min time window compared to the ALT cohort [40 min (30-53) vs 45 min (35-55); P = .057]. In multivariable models, DTN times by thrombolytic did not significantly differ when adjusting for NIHSS, age (P = .133), or race and ethnicity (P = .092). Regression models for the overall cohort indicate no significant DTN temporal trends for TNK (P = .84) after transition; nonetheless, when stratified by hospital, a single subgroup demonstrated a significant DTN upward trend (P = 0.002). CONCLUSION: In the overall cohort, TNK and ALT exhibited comparable temporal trends and at least stable DTN times. This indicates that the shift to TNK did not have an adverse impact on the DTN stroke metrics. This seamless transition is likely attributed to the similarity of inclusion and exclusion criteria, as well as the administration processes for both medications. When stratified by hospital, the three subgroups demonstrated variable DTN time trends which highlight the potential for either fatigue or unpreparedness when switching to TNK. Because our study included a multi-ethnic cohort from multiple large Texas cities, the stable DTN times after transition to TNK is likely applicable to other healthcare systems.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Enregistrements , Ténectéplase , Traitement thrombolytique , Délai jusqu'au traitement , Humains , Texas/épidémiologie , Fibrinolytiques/administration et posologie , Fibrinolytiques/effets indésirables , Mâle , Femelle , Facteurs temps , Sujet âgé , Délai jusqu'au traitement/tendances , Ténectéplase/usage thérapeutique , Ténectéplase/administration et posologie , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/diagnostic , Traitement thrombolytique/tendances , Traitement thrombolytique/effets indésirables , Adulte d'âge moyen , Résultat thérapeutique , Sujet âgé de 80 ans ou plus , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/effets indésirablesRÉSUMÉ
BACKGROUND: Individuals with minor ischaemic stroke and intracranial occlusion are at increased risk of poor outcomes. Intravenous thrombolysis with tenecteplase might improve outcomes in this population. We aimed to test the superiority of intravenous tenecteplase over non-thrombolytic standard of care in patients with minor ischaemic stroke and intracranial occlusion or focal perfusion abnormality. METHODS: In this multicentre, prospective, parallel group, open label with blinded outcome assessment, randomised controlled trial, adult patients (aged ≥18 years) were included at 48 hospitals in Australia, Austria, Brazil, Canada, Finland, Ireland, New Zealand, Singapore, Spain, and the UK. Eligible patients with minor acute ischaemic stroke (National Institutes of Health Stroke Scale score 0-5) and intracranial occlusion or focal perfusion abnormality were enrolled within 12 h from stroke onset. Participants were randomly assigned (1:1), using a minimal sufficient balance algorithm to intravenous tenecteplase (0·25 mg/kg) or non-thrombolytic standard of care (control). Primary outcome was a return to baseline functioning on pre-morbid modified Rankin Scale score in the intention-to-treat (ITT) population (all patients randomly assigned to a treatment group and who did not withdraw consent to participate) assessed at 90 days. Safety outcomes were reported in the ITT population and included symptomatic intracranial haemorrhage and death. This trial is registered with ClinicalTrials.gov, NCT02398656, and is closed to accrual. FINDINGS: The trial was stopped early for futility. Between April 27, 2015, and Jan 19, 2024, 886 patients were enrolled; 369 (42%) were female and 517 (58%) were male. 454 (51%) were assigned to control and 432 (49%) to intravenous tenecteplase. The primary outcome occurred in 338 (75%) of 452 patients in the control group and 309 (72%) of 432 in the tenecteplase group (risk ratio [RR] 0·96, 95% CI 0·88-1·04, p=0·29). More patients died in the tenecteplase group (20 deaths [5%]) than in the control group (five deaths [1%]; adjusted hazard ratio 3·8; 95% CI 1·4-10·2, p=0·0085). There were eight (2%) symptomatic intracranial haemorrhages in the tenecteplase group versus two (<1%) in the control group (RR 4·2; 95% CI 0·9-19·7, p=0·059). INTERPRETATION: There was no benefit and possible harm from treatment with intravenous tenecteplase. Patients with minor stroke and intracranial occlusion should not be routinely treated with intravenous thrombolysis. FUNDING: Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research, and the British Heart Foundation.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Ténectéplase , Humains , Ténectéplase/usage thérapeutique , Ténectéplase/administration et posologie , Mâle , Femelle , Accident vasculaire cérébral ischémique/traitement médicamenteux , Fibrinolytiques/usage thérapeutique , Fibrinolytiques/administration et posologie , Sujet âgé , Adulte d'âge moyen , Résultat thérapeutique , Études prospectives , Norme de soins , Activateur tissulaire du plasminogène/usage thérapeutique , Activateur tissulaire du plasminogène/administration et posologie , Traitement thrombolytique/méthodesRÉSUMÉ
BACKGROUND: Almost half of acute ischemic stroke patients present with mild symptoms and there are large practice variations in their treatment globally. Individuals with an intracranial occlusion who present with minor stroke are at an increased risk of early neurological deterioration and poor outcomes. Individual patient data meta-analysis in the subgroup of patients with minor deficits showed benefit of alteplase in improving outcomes; however, this benefit has not been seen with intravenous alteplase in published randomized trials. DESIGN: TEMPO-2 (A Randomized Controlled Trial of Tenecteplase Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion) is a prospective, open label with blinded outcome assessment, randomized controlled trial, designed to test the superiority of intravenous tenecteplase (0.25 mg/kg) over nonthrombolytic standard of care, with an estimated sample size of 1274 patients. Adult patients presenting with acute ischemic stroke with the National Institutes of Health Stroke Scale (NIHSS) ⩽ 5 and visible arterial occlusion or perfusion deficit within 12 h of onset are randomized to receive either tenecteplase (0.25 mg/kg) or standard of care. The primary outcome is return to baseline neurological functioning, measured by the modified Rankin scale (mRS) at 90 days. Safety outcomes include death and symptomatic hemorrhage (intra or extra-cranial). Other secondary outcomes include mRS 0-1, mRS 0-2, ordinal shift analysis of the mRS, partial, and full recanalization on follow-up computed tomography angiogram. CONCLUSION: Results of this trial will aid in determining whether there is benefit of using tenecteplase (0.25 mg/kg) in treating patients presenting with minor stroke who are at high risk of developing poor outcomes due to presence of an intracranial occlusion. DATA ACCESS STATEMENT: Data will be available upon reasonable request.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Ténectéplase , Humains , Ténectéplase/usage thérapeutique , Ténectéplase/administration et posologie , Accident vasculaire cérébral ischémique/traitement médicamenteux , Fibrinolytiques/usage thérapeutique , Fibrinolytiques/administration et posologie , Norme de soins , Mâle , Résultat thérapeutique , Femelle , Études prospectives , Activateur tissulaire du plasminogène/usage thérapeutique , Activateur tissulaire du plasminogène/administration et posologie , Sujet âgé , Adulte d'âge moyenRÉSUMÉ
OBJECTIVE: Alteplase is the current standard of care for acute ischemic stroke. Tenecteplase is a newer fibrinolytic agent with preferable administration and lower costs; however, its comparative effectiveness to alteplase remains uncertain. We set out to perform a systematic review and meta-analysis to establish the benefits and harms of tenecteplase versus alteplase for acute ischemic stroke. METHODS: We searched PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov from inception to April 2023 for randomized and non-randomized studies that compared tenecteplase versus alteplase for acute ischemic stroke. Paired reviewers independently assessed risk of bias and extracted data. We performed both conventional meta-analyses and Bayesian network meta-analyses (NMA) with random-effects models and used the GRADE approach to evaluate the certainty of evidence. Our primary efficacy outcome was excellent functional outcome at 3 months, defined as a score of 0-1 on the modified Rankin Scale. Our primary safety outcomes were symptomatic intracranial hemorrhage and all-cause mortality. RESULTS: Thirty-six studies were eligible for review, including 12 randomized (n = 5533) and 24 non-randomized studies (n = 44,956). Moderate certainty evidence showed that there was no difference between tenecteplase and alteplase in increasing the proportion of patients achieving excellent functional outcome at 3 months (odds ratio [OR], 1.10; 95% CI 0.98-1.23; risk difference [RD] 2.4%, 95% CI - 0.5 to 5.2), while moderate certainty evidence from NMA suggested that 0.25 mg/kg tenecteplase significantly improved excellent functional outcome at 3 months (OR, 1.16; 95% credible interval 1.02-1.32). Moderate certainty evidence showed that, compared to alteplase, tenecteplase may make little to no difference in the prevalence of symptomatic intracranial hemorrhage (OR, 1.12; 95% CI 0.79-1.59; RD 0.3%, 95% CI - 0.5 to 1.4), and probably reduces all-cause mortality (adjusted odds ratio [aOR], 0.44; 95% CI 0.30-0.64; RD - 4.6%; 95% CI - 5.8 to - 2.9). CONCLUSIONS: Moderate certainty evidence suggested that there was little to no difference between tenecteplase and alteplase in increasing the proportion of patients achieving excellent functional outcome at 3 months and the risk of symptomatic intracranial hemorrhage, while compared to alteplase, tenecteplase probably reduce all-cause mortality. Administration of 0.25 mg/kg tenecteplase after acute ischemic stroke is suggestive of increasing the proportion of patients that achieve excellent functional outcome at 3 months.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Essais contrôlés randomisés comme sujet , Ténectéplase , Activateur tissulaire du plasminogène , Humains , Ténectéplase/administration et posologie , Accident vasculaire cérébral ischémique/traitement médicamenteux , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/usage thérapeutique , Activateur tissulaire du plasminogène/pharmacologie , Activateur tissulaire du plasminogène/effets indésirables , Fibrinolytiques/administration et posologie , Fibrinolytiques/pharmacologie ,RÉSUMÉ
The treatment of acute ischemic stroke has improved in last few decades. While meta-analyses of several trials have established the safety and efficacy of Intravenous (IV) Tenecteplase thrombolysis, concomitant continuous transcranial doppler (TCD) ultrasound administration has not been assessed in any clinical trial. The aim of this study was to determine the effects of continuous 2 MHz TCD ultrasound during IV Tenecteplase thrombolysis for Middle cerebral artery (MCA) stroke. A total of 19 patients were included, 13 received TCD ultrasound and 6 sham TCD with IV Tenecteplase. TCD spectrum and difference in Pre and post TCD parameters were measured. Asymptomatic hemorrhagic transformation of infarct was seen in two patients. There was no mortality or clinical worsening in the sonothrombolysis group as against sham sonothrombolysis group. Median of peak systolic velocity was increased in both the sonothrombolysis (P = 0.0002) and sham sonothrombolysis group (P-value = 0.001). The difference in change in mean flow velocity between two groups, sonothrombolysis (11 cm/sec) and sham sonothrombolysis (3.5 cm/sec) were also significantly different (P = 0.014). This pilot work has established safety of continuous 30 min TCD application along with IV Tenecteplase thrombolysis and it concludes that concomitant 2 MHz TCD ultrasound administration significantly increased the MCA blood flow compared to chemothrombolysis alone.CTRI Registered Number: CTRI/2021/02/031418.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Ténectéplase , Traitement thrombolytique , Activateur tissulaire du plasminogène , Échographie-doppler transcrânienne , Humains , Ténectéplase/administration et posologie , Ténectéplase/usage thérapeutique , Échographie-doppler transcrânienne/méthodes , Mâle , Adulte d'âge moyen , Femelle , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/thérapie , Accident vasculaire cérébral ischémique/imagerie diagnostique , Traitement thrombolytique/méthodes , Fibrinolytiques/usage thérapeutique , Fibrinolytiques/administration et posologie , Sujet âgé , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/usage thérapeutique , Infarctus du territoire de l'artère cérébrale moyenne/thérapie , Infarctus du territoire de l'artère cérébrale moyenne/traitement médicamenteux , Infarctus du territoire de l'artère cérébrale moyenne/imagerie diagnostique , Résultat thérapeutique , Association thérapeutiqueRÉSUMÉ
BACKGROUND: Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial involving patients with ischemic stroke to compare tenecteplase (0.25 mg per kilogram of body weight, up to 25 mg) with placebo administered 4.5 to 24 hours after the time that the patient was last known to be well. Patients had to have evidence of occlusion of the middle cerebral artery or internal carotid artery and salvageable tissue as determined on perfusion imaging. The primary outcome was the ordinal score on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability and a score of 6 indicating death) at day 90. Safety outcomes included death and symptomatic intracranial hemorrhage. RESULTS: The trial enrolled 458 patients, 77.3% of whom subsequently underwent thrombectomy; 228 patients were assigned to receive tenecteplase, and 230 to receive placebo. The median time between the time the patient was last known to be well and randomization was approximately 12 hours in the tenecteplase group and approximately 13 hours in the placebo group. The median score on the modified Rankin scale at 90 days was 3 in each group. The adjusted common odds ratio for the distribution of scores on the modified Rankin scale at 90 days for tenecteplase as compared with placebo was 1.13 (95% confidence interval, 0.82 to 1.57; P = 0.45). In the safety population, mortality at 90 days was 19.7% in the tenecteplase group and 18.2% in the placebo group, and the incidence of symptomatic intracranial hemorrhage was 3.2% and 2.3%, respectively. CONCLUSIONS: Tenecteplase therapy that was initiated 4.5 to 24 hours after stroke onset in patients with occlusions of the middle cerebral artery or internal carotid artery, most of whom had undergone endovascular thrombectomy, did not result in better clinical outcomes than those with placebo. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by Genentech; TIMELESS ClinicalTrials.gov number, NCT03785678.).
Sujet(s)
Encéphalopathie ischémique , Accident vasculaire cérébral ischémique , Imagerie de perfusion , Ténectéplase , Thrombectomie , Activateur tissulaire du plasminogène , Humains , Encéphalopathie ischémique/imagerie diagnostique , Encéphalopathie ischémique/traitement médicamenteux , Encéphalopathie ischémique/mortalité , Encéphalopathie ischémique/chirurgie , Fibrinolytiques/administration et posologie , Fibrinolytiques/effets indésirables , Fibrinolytiques/usage thérapeutique , Hémorragies intracrâniennes/induit chimiquement , Hémorragies intracrâniennes/imagerie diagnostique , Perfusion , Imagerie de perfusion/méthodes , Accident vasculaire cérébral/imagerie diagnostique , Accident vasculaire cérébral/traitement médicamenteux , Accident vasculaire cérébral/mortalité , Accident vasculaire cérébral/chirurgie , Ténectéplase/administration et posologie , Ténectéplase/effets indésirables , Ténectéplase/usage thérapeutique , Thrombectomie/effets indésirables , Thrombectomie/méthodes , Activateur tissulaire du plasminogène/administration et posologie , Activateur tissulaire du plasminogène/effets indésirables , Activateur tissulaire du plasminogène/usage thérapeutique , Résultat thérapeutique , Méthode en double aveugle , Accident vasculaire cérébral ischémique/imagerie diagnostique , Accident vasculaire cérébral ischémique/traitement médicamenteux , Accident vasculaire cérébral ischémique/mortalité , Accident vasculaire cérébral ischémique/chirurgie , Infarctus du territoire de l'artère cérébrale moyenne/imagerie diagnostique , Infarctus du territoire de l'artère cérébrale moyenne/traitement médicamenteux , Infarctus du territoire de l'artère cérébrale moyenne/chirurgie , Artériopathies carotidiennes/imagerie diagnostique , Artériopathies carotidiennes/traitement médicamenteux , Artériopathies carotidiennes/chirurgie , Encéphale/vascularisation , Encéphale/imagerie diagnostique , Délai jusqu'au traitementRÉSUMÉ
BACKGROUND: In recent years, Tenecteplase (TNK), a genetically modified variant of alteplase, has been verified as a potential substitute for alteplase in the reperfusion therapy of acute ischemic stroke (AIS). Given the emergence of new randomized controlled trials (RCTs) of this subject, a meta-analysis was conducted to evaluate the present comparative evidence regarding the efficacy and safety outcomes of TNK and alteplase in thrombolysis for AIS. METHODS: Following predefined inclusion criteria, we searched the databases of PubMed, Web of Science, and Cochrane Library. RCTs satisfying our inclusion criteria were selected for meta-analysis. Outcome indicators were categorized into efficacy outcomes (early vessel recanalization, excellent recovery, good recovery and early neurological improvement) and safety outcomes (poor recovery, symptomatic intracerebral hemorrhage, parenchymal hemorrhage type 2(PH2) post thrombolysis, and mortality). We extracted data on efficacy outcomes and safety outcomes for patients with AIS in the TNK group at a dose of 0.25 mg/kg and the alteplase group at a dose of 0.9 mg/kg, and expressed the relative risks between the 2 groups as odds ratios (ORs) and 95% confidence intervals (CIs) using the Mantel-Haenszel method. For further insight, we performed a network meta-analysis using a Bayesian framework to compare different doses of TNK (0.1, 0.25, 0.32, and 0.4 mg/kg) with alteplase (0.9 mg/kg). RESULTS: A total of 2994 patients in 9 RCTs comparing efficacy and safety outcomes in patients with AIS treated with TNK and alteplase were included. In a pairwise analysis of TNK 0.25 mg/kg and alteplase 0.9 mg/kg, regarding efficacy outcomes, the aggregated results show that TNK 0.25 mg/kg statistically significant increased early vessel recanalization (N = 368, TNK vs. alteplase, OR: 2.07,95%CI: [1.19,3.59], I2 = 0%) and excellent recovery (N = 3548, TNK vs. alteplase, OR: 1.15,95%CI: [1.01,1.32], I2 = 0%). There was no significant difference in good recovery (N = 3486, TNK vs. alteplase, OR: 1.38,95%CI: [0.89,2.15], I2 = 84%) or early neurological improvement (N = 1686, TNK vs. alteplase, OR: 1.06,95%CI: [0.87,1.28], I2 = 24%) between the TNK 0.25 mg/kg group and the alteplase 0.9 mg/kg group. In the safety outcomes, pooled results showed no significant difference in poor recovery (N = 3548, TNK vs. alteplase, OR: 0.94,95%CI: [0.81,1.10], I2 = 0%) and symptomatic intracerebral hemorrhage (N = 3567, TNK vs. alteplase, OR: 1.06,95%CI: [0.70,1.60], I2 = 0%) and PH2(N = 3103, TNK vs. alteplase, OR: 1.26,95%CI:[0.39,4.07], I2 = 56%)and mortality (N = 3447, TNK vs. alteplase, OR: 0.99,95%CI: [0.80,1.23], I2 = 33%) between the TNK group and the alteplase group. In a network meta-analysis, competing treatments were not significantly different from one another (TNK 0.1 mg/kg, TNK 0.25 mg/kg, TNK 0.32 mg/kg, TNK 0.4 mg/kg, alteplase 0.9 mg/kg) in either efficacy outcomes or safety outcomes. CONCLUSION: In this analysis of 9 RCTs in patients with AIS, TNK 0.25 mg/kg was comparable to alteplase 0.9 mg/kg from the perspective of efficacy outcomes and safety outcomes after thrombolysis within 4.5 h of AIS occurrence.
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Essais contrôlés randomisés comme sujet , Ténectéplase , Traitement thrombolytique , Activateur tissulaire du plasminogène , Humains , Activateur tissulaire du plasminogène/usage thérapeutique , Activateur tissulaire du plasminogène/effets indésirables , Activateur tissulaire du plasminogène/administration et posologie , Ténectéplase/usage thérapeutique , Ténectéplase/administration et posologie , Essais contrôlés randomisés comme sujet/méthodes , Fibrinolytiques/usage thérapeutique , Fibrinolytiques/administration et posologie , Fibrinolytiques/effets indésirables , Accident vasculaire cérébral ischémique/traitement médicamenteux , Traitement thrombolytique/méthodes , Traitement thrombolytique/effets indésirables , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Nearly half of patients with acute ischemic stroke who undergo intravenous thrombolysis (IVT) fail to achieve excellent functional outcomes. Early administration of tirofiban after IVT may improve patient outcomes. OBJECTIVE: To evaluate the efficacy and safety of early tirofiban administration after intravenous tenecteplase in patients with acute ischemic stroke. METHODS AND DESIGN: The ADVENT trial is a multicenter, randomized, parallel-controlled, double-blind clinical trial. A total of 1084 patients undergoing IVT without subsequent endovascular treatment will be recruited from multiple hospitals in China. Subjects will be randomized in a 1:1 ratio to receive tirofiban or placebo, which will be infused within 6 h after IVT until 24 h after IVT, at 0.4 µg/kg/min for 30 min and then at 0.1 µg/kg/min. The primary efficacy outcome is the proportion of patients with excellent functional outcomes (modified Rankin Scale (mRS) ⩽ 1) at 90 days. Secondary outcomes include the proportion of patients with favorable functional outcomes (mRS ⩽ 2) at 90 days and neurological functional assessments evaluated during hospitalization. Symptomatic intracranial hemorrhage will be the primary safety outcome. Mortality and other adverse events will be recorded. DISCUSSION: This pivotal trial will provide important data on the early administration of antiplatelet therapy after IVT and may promote progress in treatment standards. TRIAL REGISTRY: ClinicalTrials.gov (NCT06045156).
Sujet(s)
Fibrinolytiques , Accident vasculaire cérébral ischémique , Traitement thrombolytique , Tirofiban , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Administration par voie intraveineuse , Encéphalopathie ischémique/traitement médicamenteux , Méthode en double aveugle , Fibrinolytiques/administration et posologie , Fibrinolytiques/usage thérapeutique , Fibrinolytiques/effets indésirables , Accident vasculaire cérébral ischémique/traitement médicamenteux , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/usage thérapeutique , Antiagrégants plaquettaires/effets indésirables , Ténectéplase/administration et posologie , Ténectéplase/usage thérapeutique , Traitement thrombolytique/méthodes , Tirofiban/administration et posologie , Tirofiban/usage thérapeutique , Résultat thérapeutique , Essais contrôlés randomisés comme sujet , Études multicentriques comme sujetRÉSUMÉ
Synergistic effects of fibrinolytic and additional antithrombotic treatment during cardiopulmonary resuscitation in out-of-hospital cardiac arrest of assumed cardiac origin were evaluated retrospectively. Data were drawn from electronic files of the physician-staffed Emergency Medical Services Tyrol. During a 22-month observation period 53 adult patients were treated with tenecteplase (mean 7641 IU), 19 (32.1%) of whom received additional antithrombotic treatment with heparin (4000-5000 IU) and acetylsalicylic acid (250-500 mg). Lasting return of spontaneous circulation occurred in four of 34 patients who received fibrinolytic treatment only and in seven of 19 patients with additional antithrombotic treatment (p = 0.037). Four of five patients who were discharged from hospital had received additional antithrombotic treatment during CPR and were in appropriate neurological status (CPC 1). Considering the small sample size in this retrospective study, the argument may be still be made that fibrinolytic and adjunctive antithrombotic treatment during cardiopulmonary resuscitation in out-of-hospital cardiac arrest of assumed cardiac origin may increase the chances for survival.